New biological insights into osteosarcoma-lessons from single cell sequencing studies

Area of Science:

• Oncology
• Genomics
• Immunology

Background:

• Osteosarcoma (OS) is a primary bone cancer in children and adolescents, marked by significant tumor heterogeneity and an immunosuppressive tumor microenvironment (TME).
• This heterogeneity and immunosuppressive TME limit the effectiveness of current chemotherapy and emerging immunotherapies.
• Single-cell RNA sequencing (scRNA-seq) and single-nucleus RNA sequencing (snRNA-seq) offer high-resolution insights into OS cellular composition.

Purpose of the Study:

• To review the current applications of single-cell transcriptomics in osteosarcoma research.
• To highlight methodological challenges and recent advancements in single-cell studies of OS.
• To discuss the implications of these findings for improving osteosarcoma immunotherapies.

Main Methods:

• Review of existing literature on single-cell transcriptomics (scRNA-seq, snRNA-seq) in osteosarcoma.
• Analysis of identified malignant, immune, and stromal cell populations within OS tumors.
• Discussion of emerging techniques like spatial transcriptomics and integration with other omics data.

Main Results:

• scRNA-seq and snRNA-seq have identified diverse cell populations in OS, including proliferative, inflammatory, and angiogenic states, alongside immunosuppressive myeloid cells and exhausted T cells.
• Complex cell-cell communication networks contributing to tumor progression and immune evasion have been elucidated.
• Methodological challenges include tissue dissociation of mineralized bone and limited fresh specimen availability, with snRNA-seq and improved protocols showing promise.

Conclusions:

• Single-cell transcriptomics provides crucial insights into the OS tumor microenvironment and its heterogeneity.
• Overcoming methodological barriers is key to advancing OS research using single-cell technologies.
• Integrating single-cell data with other modalities holds significant potential for developing more effective osteosarcoma immunotherapies.